Sunday, October 18, 2026

The Healthcare Consulting Playbook

Hi all,

I am starting this 

Blog Series: Understanding Healthcare Consulting in the Real World

My first blog will be

Blog 1: Healthcare Data Analytics — How Excel, SQL and Power BI Help Healthcare Organizations Make Better Decisions

Introduction

Healthcare organizations generate enormous amounts of information every day. Hospitals record admissions, diagnostic centers process thousands of tests, insurers evaluate claims, and pharmaceutical companies monitor product performance.

Yet collecting data does not automatically improve healthcare. The real challenge is turning information into decisions that improve patient experience, operational efficiency, and financial performance.

This is where healthcare data analytics becomes valuable.

Healthcare analytics professionals help organizations understand what is happening, investigate why it is happening, and identify what actions may improve the situation.



What does healthcare data analytics mean in practice?

Imagine a multispecialty hospital where patients frequently complain about long waiting times. Management suspects that the hospital needs more doctors, but hiring additional staff would increase expenditure.

Instead of immediately recommending recruitment, an analyst investigates the underlying problem.

They examine appointment schedules, registration times, consultation durations, staffing patterns, and patient arrival volumes. The analysis may reveal that delays occur primarily during specific hours or because registration and consultation schedules are poorly coordinated.

The hospital can then test scheduling improvements before committing to additional recruitment.

This is the practical value of healthcare analytics: replacing assumptions with evidence.

How Excel, SQL and Power BI fit together

1. Excel: Exploring and organizing information

Excel is useful for initial data cleaning, pivot tables, calculations, reconciliation, and quick analysis.

A healthcare analyst might use it to compare monthly revenue, calculate average waiting times, investigate rejected insurance claims, or prepare an operational report.

2. SQL: Retrieving information from databases

Healthcare information is often stored across databases containing patient encounters, appointments, billing records, pharmacy transactions, and insurance claims.

SQL enables analysts to retrieve and combine relevant records. For example, an analyst could identify claims that were submitted but remain unpaid, subject to appropriate access permissions and data governance.

3. Power BI: Communicating insights through dashboards

Power BI helps transform analyzed data into interactive reports for hospital administrators and department heads.

A dashboard could display bed occupancy, patient volumes, revenue trends, appointment cancellations, and claim rejection rates. Managers can use filters to investigate specific departments or periods.

The objective is not simply to create attractive charts. It is to help decision-makers recognize problems early and take appropriate action.

A practical healthcare analytics case study

Consider a hypothetical hospital with rising insurance claim rejections.

The consulting team follows a structured approach:

  • Define the problem: Establish the baseline rejection rate and financial impact.

  • Collect data: Review claim records, rejection codes, billing processes, and submission timelines.

  • Analyze patterns: Determine whether rejections are associated with missing documentation, coding errors, eligibility checks, or payer-specific requirements.

  • Develop recommendations: Introduce targeted documentation checks, staff training, or workflow changes.

  • Monitor outcomes: Track rejection rates, resubmission times, and payment turnaround.

The analyst should distinguish between a rejected claim, a delayed claim, and a claim that is ultimately uncollectible. These situations have different operational and financial implications.

Any proposed intervention must also be checked against applicable billing rules and payer contracts.

Important metrics in healthcare analytics

Useful measures depend on the organization's goals, but may include:

  • Average patient waiting time

  • Bed occupancy and bed turnover

  • Appointment no-show rate

  • Claims rejection rate

  • Average days in accounts receivable

  • Cost per patient encounter

  • Readmission rate, with appropriate clinical adjustment

  • Patient experience measures

Metrics should have clear definitions, reliable data sources, and accountable owners. A dashboard cannot compensate for inaccurate data or poorly defined indicators.

Skills needed for a healthcare analytics career

A strong foundation includes Excel, SQL, data visualization, basic statistics, analytical reasoning, and communication.

Healthcare-specific knowledge adds value because hospital workflows, medical terminology, privacy requirements, and reimbursement processes differ from those in many other industries.

Python may be useful for advanced analysis, automation, or predictive modeling, but it is not mandatory for every entry-level analytics position.

Conclusion

Healthcare analytics is most valuable when it connects technical analysis with operational understanding. Excel helps explore data, SQL retrieves it, and Power BI communicates the findings. Together, these tools can support better decisions—but the real impact comes from using reliable evidence to improve a healthcare process.

Suggested audience: Aspiring healthcare analysts, business analysts, hospital administrators, and professionals transitioning into healthcare technology.


Blog 2: Healthcare Business and Strategy Consulting — Helping Healthcare Organizations Make Better Business Decisions

Introduction

Healthcare organizations must balance clinical quality, financial sustainability, regulatory requirements, workforce constraints, and patient expectations.

A hospital may want to expand into a new city. A pharmaceutical company may be evaluating a product launch. A healthcare startup may need to decide which customer segment to serve first.

These are not simply operational questions. They involve strategic choices with significant financial and organizational consequences.

Healthcare strategy consultants help leadership teams evaluate such decisions systematically.

What do healthcare strategy consultants actually do?

Their work commonly includes market research, growth strategy, financial analysis, commercial due diligence, operating model design, and support for major transformation programs.

The exact responsibilities vary by firm and project. Strategy specialists may focus on executive-level decisions, while other consultants concentrate on implementation, technology, or operational improvement.

Example: Should a hospital open a new branch?

Suppose a hospital group is considering a new facility in a growing urban area.

A superficial analysis might focus on population growth and assume that demand will be sufficient. A rigorous consulting project examines several questions.

Market demand: How many people live in the catchment area? What conditions are prevalent? How far do residents currently travel for care?

Competition: Which hospitals, clinics, and diagnostic centers already serve the area? What services are underserved?

Financial feasibility: What capital investment is required? What patient volumes, prices, operating costs, and staffing levels are needed for financial sustainability?

Operational readiness: Can the organization recruit clinicians, establish referral networks, maintain reliable supplies, and meet relevant requirements?

Strategic fit: Does the proposed location support the hospital group's long-term goals?

Consultants may build financial scenarios, interview stakeholders, compare competitors, and assess risks before recommending whether to proceed, revise the plan, or reject the investment.

The recommendation should explain its assumptions and uncertainties rather than promise guaranteed success.

Common types of healthcare strategy projects

Market entry and expansion: Assessing opportunities for hospitals, diagnostics businesses, medical technology companies, or healthcare platforms.

Growth and portfolio strategy: Deciding which services, therapeutic areas, or customer segments deserve investment.

Commercial due diligence: Evaluating a healthcare business before an investor or company acquires it.

Pricing and market access: Studying how a medicine, diagnostic service, or healthcare solution may reach eligible customers within relevant reimbursement and regulatory frameworks.

Digital transformation: Helping organizations determine where technology could improve service delivery, information access, or operational performance.

Performance improvement: Identifying opportunities to improve costs, productivity, revenue processes, and quality.

How consultants structure a problem

A useful consulting approach is to break a broad question into smaller, testable questions.

For example, if a hospital's profitability is declining, the team might investigate:

  1. Has patient volume changed?

  2. Has the mix of services changed?

  3. Are reimbursement rates or collection rates lower?

  4. Have staffing, procurement, or facility costs increased?

  5. Are certain departments operating below capacity?

  6. Could quality problems or delays be affecting demand and performance?

The team then prioritizes the questions that are most likely to explain the problem and can be tested using available evidence.

What does the final deliverable look like?

Depending on the engagement, the output may include an executive presentation, a market assessment, a financial model, an implementation roadmap, or a set of performance measures.

The work is not complete merely because the presentation is finished. Recommendations must be realistic, financially defensible, and compatible with clinical responsibilities and regulatory obligations.

Conclusion

Healthcare strategy consulting is about helping organizations make important decisions under uncertainty. It combines research, analytical thinking, financial reasoning, stakeholder engagement, and clear communication.

The best recommendations do more than identify an attractive opportunity: they explain the conditions under which that opportunity is achievable and how the organization should act on it.

Suggested audience: MBA students, healthcare entrepreneurs, corporate strategy professionals, investors, and aspiring management consultants.


Blog 3: Medical and Clinical Consulting — Connecting Clinical Expertise with Better Healthcare Systems

Introduction

Healthcare decisions cannot be evaluated through financial performance alone. A service may appear efficient while compromising clinical quality, or a cost-saving proposal may create additional risks for patients.

Medical and clinical consulting brings clinical knowledge, evidence-based practice, and healthcare delivery expertise into organizational decision-making.

However, the term covers several different kinds of work, and it is important to distinguish them.

What is medical or clinical consulting?

Depending on the employer and role, it may involve:

  • Clinical pathway and care-model improvement

  • Quality and patient safety initiatives

  • Clinical governance and audit

  • Healthcare technology and clinical informatics

  • Medical affairs and scientific advisory work

  • Clinical research and pharmaceutical development

  • Evidence evaluation and health outcomes analysis

A physician advising a hospital on clinical quality performs a different function from a pharmaceutical medical affairs professional or a consultant helping implement an electronic health record system.

These roles may overlap, but they have distinct responsibilities.

Example: Improving the discharge process

Consider a hospital where patients experience avoidable delays before discharge.

The problem may involve several departments: the treating team, nursing staff, pharmacy, diagnostic services, billing, and transport coordination.

A clinical improvement team maps the existing process and investigates where delays occur. It consults relevant clinicians and reviews patient safety requirements.

Potential interventions might include earlier discharge planning, clearer responsibility for pending tasks, improved medication reconciliation, and better coordination between departments.

The team should measure both operational and clinical outcomes, such as time from discharge decision to departure, medication discrepancies, follow-up completion, and unplanned returns where appropriate.

A shorter discharge time is not automatically a better outcome. Patients must still be clinically ready for discharge, understand their instructions, and have an appropriate follow-up plan.

The role of evidence-based practice

Clinical consulting should draw on appropriate research, professional guidance, local protocols, and patient needs.

Consultants may help organizations review whether care pathways are consistent with current evidence, whether documentation is adequate, and whether outcome measures are being collected reliably.

They must also recognize that published evidence may not apply equally to every patient population or care setting.

Clinical expertise and digital transformation

Healthcare technology projects often require a bridge between clinicians and technical teams.

For example, when implementing an electronic health record, consultants may help map clinical workflows, define information requirements, identify safety risks, coordinate user testing, and plan staff training.

A system can be technically functional yet fail in practice if it disrupts clinical work or creates unnecessary documentation burdens.

Successful implementation therefore requires input from the people who will use the system.

Who can enter this field?

Requirements depend on the position.

Clinical advisory roles may require a medical, nursing, pharmacy, or other relevant professional qualification. Clinical research roles may require specialized research experience. Health informatics and quality improvement positions may also be open to candidates from technology, analytics, public health, or healthcare management backgrounds.

Non-clinical consultants should not present themselves as licensed clinicians or make independent treatment decisions beyond their qualifications and authority.

Conclusion

Medical and clinical consulting focuses on improving the safety, quality, effectiveness, and delivery of healthcare. Its value lies in combining evidence and clinical judgment with practical organizational change.

The ultimate goal is not merely to improve a metric. It is to support care that is safe, appropriate, accessible, and responsive to patients' needs.

Suggested audience: Doctors exploring non-clinical careers, nurses, pharmacists, clinical researchers, quality professionals, and healthcare technology specialists.


Blog 4: Hospital Management and Operations Consulting — Making Healthcare Services Work Better

Introduction

A hospital can employ highly skilled clinicians and possess advanced equipment yet still struggle with long waiting times, inefficient bed utilization, stock shortages, billing delays, or poor coordination.

These challenges often arise from how work moves across departments rather than from a single employee or service.

Hospital operations consulting examines these interconnected processes and helps organizations improve the way care is delivered.

What do hospital operations consultants do?

Typical assignments involve patient flow, workforce planning, procurement, bed management, operating room utilization, outpatient scheduling, billing workflows, and service quality.

The objective is to improve performance without compromising clinical standards or staff well-being.

Example: Why are patients waiting so long?

Imagine an outpatient department where patients regularly wait more than an hour after arriving for an appointment.

Before recommending more doctors, consultants examine the entire patient journey.

Step 1: Map the process. Document registration, payment, triage where applicable, consultation, diagnostics, and follow-up.

Step 2: Measure the baseline. Determine when patients arrive, when each step begins and ends, and where queues form.

Step 3: Identify the bottleneck. The main delay might occur at registration, during peak consultation periods, or because diagnostic results are unavailable when clinicians need them.

Step 4: Test improvements. Options might include staggered appointments, revised staffing schedules, better queue coordination, or clearer routing for patients.

Step 5: Monitor the results. Track waiting times, patients served, staff workload, missed appointments, and patient experience.

This approach avoids treating every operational problem as a staffing problem.

Key operational indicators

Hospitals may monitor:

  • Patient waiting time by service

  • Bed occupancy and discharge patterns

  • Operating room utilization and cancellation rates

  • Average length of stay, interpreted alongside case complexity

  • Staff overtime and workload

  • Inventory availability and wastage

  • Billing turnaround time

  • Patient complaints and experience measures

Each indicator needs context. High bed occupancy, for instance, may indicate strong utilization, but persistently excessive occupancy can reduce flexibility and contribute to delays.

Lean thinking and continuous improvement

Operations consultants may use process mapping, root-cause analysis, standard work, and continuous improvement methods.

A useful distinction is between removing unnecessary steps and simply asking staff to work faster. Sustainable improvement redesigns the process, clarifies responsibilities, and provides appropriate resources.

Technology and hospital operations

Digital scheduling, electronic records, inventory systems, and operational dashboards can support better coordination.

However, technology should address a clearly defined problem. Automating a poorly designed process may simply make the existing inefficiency happen faster.

Successful changes also require training, staff engagement, clear ownership, and ongoing monitoring.

What is the difference between hospital management and operations consulting?

Hospital managers are responsible for ongoing operations within their organizations. Operations consultants are typically engaged to investigate a defined problem, provide specialist expertise, or support a change initiative.

Some consultants help implement changes and track results; others primarily provide analysis and recommendations. The division depends on the project.

Conclusion

Hospital operations consulting connects process improvement with patient care. By understanding workflows, measuring performance, and working with clinical and administrative teams, consultants can help hospitals use resources more effectively while protecting safety and quality.

Suggested audience: Hospital administrators, healthcare management students, MHA candidates, operations professionals, and process improvement specialists.


Blog 5: The Complete Healthcare Consulting Industry — Who the Clients Are, What Firms Do, and How the Specializations Connect

Introduction

Healthcare consulting is not one single profession. It is a broad industry serving organizations that deliver, finance, research, manufacture, regulate, and support healthcare services.

Some projects focus on executive strategy. Others involve analytics, clinical improvement, digital systems, financial performance, or day-to-day operations.

Understanding these differences helps organizations select the right expertise and helps aspiring consultants choose a suitable career path.

The major client groups

1. Hospitals and healthcare providers

Consultants may help improve patient flow, service quality, financial sustainability, workforce planning, expansion decisions, or digital systems.

2. Health insurers and other payers

Projects may involve claims operations, member experience, payment models, utilization management, analytics, and administrative efficiency.

3. Pharmaceutical and biotechnology companies

Work may include market research, portfolio strategy, commercial planning, clinical development operations, supply chain improvement, and market access.

4. Medical technology and diagnostic businesses

Consultants may evaluate market opportunities, service delivery models, product adoption, equipment utilization, and technology implementation.

5. Healthcare startups and digital health companies

Projects can include business model development, customer research, product strategy, growth planning, and operational design.

6. Governments, public health agencies, and nonprofit organizations

Assignments may involve service planning, healthcare access, program evaluation, resource allocation, and health system strengthening.

7. Investors and private capital firms

Consultants may assess a healthcare business's market position, growth potential, operational performance, and risks before an investment or acquisition.

What types of consulting firms serve the industry?

The categories overlap, and individual firms may provide several kinds of services.

  • Strategy-led consulting firms: McKinsey, Boston Consulting Group (BCG), and Bain & Company work on selected healthcare strategy and transformation engagements.

  • Professional services and advisory firms: Deloitte, PwC, EY, and KPMG offer relevant combinations of strategy, risk, technology, deals, and operational advisory.

  • Technology and transformation providers: Accenture, Cognizant, IBM, and NTT DATA can support healthcare technology, analytics, digital transformation, and business process initiatives.

  • Life sciences specialists: IQVIA, ZS, L.E.K. Consulting, ClearView Healthcare Partners, and Simon-Kucher have relevant expertise across selected pharmaceutical, biotechnology, medical technology, commercial, and market strategy problems.

  • Healthcare-focused specialist firms: Huron, Chartis, and other specialized advisors work on selected provider, health system, performance improvement, or healthcare management challenges.

These are illustrative categories, not an authoritative ranking. Service offerings vary by geography, practice, and engagement.

How the specializations work together

Consider a hospital group planning to expand its services while struggling with operating costs.

The strategy team evaluates demand, competition, and investment feasibility. The analytics team studies patient volumes, revenue, costs, and service utilization. The operations team investigates patient flow, staffing, and procurement. Clinical specialists evaluate whether proposed service models meet care requirements. Technology specialists assess the systems needed to support the expansion.

The leadership team can then consider a coordinated recommendation based on commercial feasibility, operational readiness, clinical quality, and financial risk.

This is why complex healthcare projects often involve multidisciplinary teams rather than one consultant working in isolation.

What skills matter across healthcare consulting?

Several capabilities are useful across specializations:

  • Structured problem-solving

  • Research and critical thinking

  • Data interpretation

  • Clear written and verbal communication

  • Stakeholder management

  • Project planning

  • Ethical handling of confidential information

  • Understanding of healthcare delivery and regulation relevant to the role

Specialist skills differ. An analytics role may emphasize SQL and Power BI, while a strategy role may place greater weight on market assessment and financial modeling. A clinical advisory role may require professional credentials, and a technology transformation role may require experience with healthcare information systems.

Career paths: Choosing the right entry point

For data-oriented candidates: Consider healthcare data analyst, business intelligence analyst, healthcare business analyst, or health informatics roles.

For business and management candidates: Explore healthcare consulting analyst, strategy analyst, market research analyst, or healthcare transformation roles.

For clinical professionals: Look into clinical quality improvement, medical affairs, clinical operations, health informatics, and healthcare advisory positions that match your qualifications.

For hospital management candidates: Consider hospital operations, performance improvement, patient experience, process excellence, or healthcare project management.

Job titles and eligibility criteria vary considerably by employer. Review actual job descriptions instead of assuming that every consulting position requires the same degree or toolset.

How to evaluate whether a consulting project succeeded

A successful project should be judged against its original objectives, baseline, implementation quality, and relevant safeguards.

Depending on the assignment, evaluation may include operational efficiency, financial sustainability, patient experience, service access, clinical quality, or adoption of a new system.

Consultants should distinguish between recommendations made, actions implemented, and outcomes actually demonstrated. Improvements can be influenced by external factors, so attributing every change to the consulting engagement would be misleading.

Conclusion

Healthcare consulting brings together business strategy, analytics, clinical knowledge, operational improvement, technology, and organizational change.

The most valuable consultants understand both the numbers and the real-world setting in which those numbers are generated. Their work is not simply about producing presentations or dashboards; it is about helping healthcare organizations make better decisions and implement meaningful improvements.

For anyone entering this industry, the best starting point is to identify a specialization, build the relevant technical and domain skills, and learn how to solve practical healthcare problems with evidence, integrity, and measurable objectives.

Thursday, October 15, 2026

The Economics of Vaccines: Who Pays, Who Profits, and Who Benefits?

 


The Economics of Vaccines: Who Pays, Who Profits, and Who Benefits?

Understanding the real cost of vaccination, pharmaceutical profits, government policies, and the value of disease prevention

Introduction: Is a vaccine an expense or an investment?

When we discuss vaccines, we usually focus on health: preventing infections, reducing hospital admissions, and saving lives.

But there is another important question:

What is the economic value of preventing a disease before it happens?

A vaccine has a manufacturing cost, a selling price, a distribution cost, and a public health benefit. It may require substantial investment before it becomes available, yet successful vaccination can prevent medical expenses, lost working days, disability, and premature deaths.

This makes vaccination more than a medical intervention. It is also an economic decision involving individuals, governments, healthcare systems, and pharmaceutical companies.

To understand this relationship, we need to examine both the cost of vaccination and the cost of not vaccinating.

1. How much does a vaccine really cost?

The price paid for a vaccine is only one part of its total economic cost.

The full cost may include:

  • Research and development

  • Clinical trials and regulatory approval

  • Manufacturing and quality control

  • Packaging, transportation, and storage

  • Healthcare workers' time and vaccination services

  • Public awareness campaigns and safety monitoring

For some vaccines, maintaining a cold chain is essential to preserve their effectiveness. This adds transportation, equipment, electricity, and storage costs.

A vaccine that costs relatively little to manufacture may still have a higher final price because of research expenses, production requirements, distribution, procurement arrangements, and commercial decisions.

However, a high price does not automatically mean a vaccine offers good value. Its cost should be assessed alongside its safety, effectiveness, duration of protection, and the disease burden it prevents.

2. Who pays for vaccination?

The financial responsibility differs from country to country and from vaccine to vaccine.

Governments: Public vaccination programmes use taxpayer money and public budgets to purchase vaccines and deliver immunisation services.

Individuals and families: People may pay for vaccines privately, travel to vaccination centres, or lose working hours while receiving a dose.

Insurance providers: Depending on the country and policy, insurers may cover eligible vaccinations and related services.

International organisations and donors: Organisations such as Gavi, the Vaccine Alliance, and UNICEF help finance or procure vaccines for eligible countries and immunisation programmes.

In India, routine childhood immunisation through the Universal Immunisation Programme is publicly funded for eligible beneficiaries. Other vaccines may be available through private healthcare providers, depending on the vaccine and applicable recommendations.

The central economic question is not simply who pays the bill. It is whether the costs and benefits are distributed fairly.

3. How do pharmaceutical companies make money from vaccines?

Vaccine development requires scientific expertise, clinical research, manufacturing facilities, regulatory compliance, and ongoing safety monitoring.

Companies may earn revenue by selling vaccines to governments, international procurement agencies, hospitals, and private healthcare providers.

Their financial performance depends on factors such as:

  • Research and development expenditure

  • Production capacity and manufacturing yields

  • Patent protection and licensing arrangements

  • Competition from other manufacturers

  • Government contracts and negotiated prices

  • Demand, public procurement, and market access

Successful vaccine development can generate significant commercial returns. However, not every vaccine project succeeds, and development costs and commercial risks vary considerably.

Public funding can also support vaccine research, clinical infrastructure, and advance purchase agreements. Consequently, the economics of a vaccine may involve both private investment and public contributions.

An important distinction: Company revenue is not the same as profit, and profit alone does not establish whether a vaccine is overpriced. A fair assessment requires information about costs, public subsidies, pricing, competition, and health outcomes.

4. The hidden economic cost of not vaccinating

Consider a vaccine that prevents a disease capable of causing hospitalisation.

If vaccination reduces the number of cases, it may also reduce spending on consultations, medicines, hospital beds, intensive care, and rehabilitation.

Families may avoid travel expenses, unpaid leave, and the financial stress associated with caring for a seriously ill relative.

Society may benefit from fewer school absences, fewer missed working days, and lower pressure on healthcare facilities.

These benefits can extend beyond the vaccinated individual. For certain infections, higher vaccination coverage can reduce transmission and help protect people who are particularly vulnerable.

However, the size of the economic benefit depends on the disease, the vaccine's effectiveness, how long protection lasts, vaccination coverage, and the cost of delivering the programme.

Prevention is not automatically the cheapest option in every circumstance. It must be evaluated using real costs and expected outcomes.

5. COVID-19 vaccines: A major economic case study

The COVID-19 pandemic demonstrated how infectious diseases can disrupt an entire economy.

Hospitals faced extraordinary demand, businesses closed or reduced operations, international travel declined, and millions of people experienced illness or lost income.

Governments spent substantial sums on healthcare, vaccine procurement, public health programmes, and economic support.

Vaccination programmes aimed to reduce the burden of severe illness and death and help healthcare systems manage the pandemic.

But evaluating the economics of COVID-19 vaccines requires more than comparing purchase prices.

A complete analysis should consider:

  1. The cost of purchasing and administering doses.

  2. The reduction in severe disease and hospitalisation.

  3. The effect of vaccination on transmission, where demonstrated.

  4. Differences in protection across age groups and risk categories.

  5. Adverse effects and the cost of identifying and treating them.

  6. Changes in variants, prior immunity, and the duration of protection.

  7. The economic effects of infection, healthcare disruption, and public health restrictions.

The benefits and costs varied across countries and over time. Therefore, the economic value of a COVID-19 vaccination programme should be assessed in its particular context rather than reduced to a universal claim that every dose always saves a fixed amount of money.

6. Cost-effectiveness: How do economists judge a vaccine?

Healthcare economists often use cost-effectiveness analysis to compare alternative ways of improving health.

They ask:

How much additional health benefit does a vaccination programme provide for its additional cost compared with an alternative?

One common measure is the incremental cost-effectiveness ratio, or ICER.

It compares the difference in costs between two strategies with the difference in their health outcomes.

Health outcomes may be measured in quality-adjusted life-years (QALYs), disability-adjusted life-years (DALYs) averted, infections prevented, or other appropriate measures.

A vaccine may be considered good value if its additional health benefits justify its additional cost under the decision-maker's criteria.

Yet cost-effectiveness is not the only consideration. Governments also need to assess affordability, budget impact, equity, implementation capacity, and the consequences of leaving vulnerable groups unprotected.

A programme can be cost-effective in theory but difficult to finance immediately. Conversely, a programme may be affordable without being the most efficient use of available resources.

7. Vaccine economics and inequality

Vaccination can reduce health inequalities, but unequal access can also reinforce them.

People in wealthier areas may have easier access to private clinics, transport, health information, and time away from work. Rural communities and disadvantaged populations may face barriers involving distance, availability, awareness, and service delivery.

Even when a vaccine is provided free of charge, indirect costs can remain.

For example, a daily-wage worker may lose income travelling to a vaccination centre. A parent may need to miss work to take a child for immunisation.

Governments can reduce these barriers through outreach services, reliable vaccine supply, convenient clinic hours, public communication, and targeted programmes for underserved populations.

Equitable access is therefore both a public health objective and an economic consideration.

8. Are expensive vaccines always better?

No. Price alone cannot establish the quality or value of a vaccine.

A more expensive vaccine might offer advantages in particular circumstances, such as broader protection, a different dosing schedule, or a longer duration of protection. Those advantages must be demonstrated with appropriate evidence.

A lower-priced vaccine may provide excellent value if it offers suitable protection, meets quality standards, and can be delivered efficiently.

Comparisons should consider:

  • Safety and effectiveness

  • Duration of protection

  • Number of doses required

  • Storage and delivery requirements

  • Disease burden in the target population

  • Total programme costs

  • Evidence on cost-effectiveness

Procurement decisions should be based on reliable evidence, transparent pricing, quality assurance, and the health needs of the population.

9. The future of vaccine economics

Several developments could influence the cost and availability of vaccines in the coming years.

New technologies: Advances in vaccine platforms may shorten development timelines or improve manufacturing flexibility, although they do not eliminate the need for rigorous testing and quality control.

Competition and local manufacturing: Additional qualified manufacturers can sometimes improve supply security and reduce prices.

Better procurement: Transparent contracts, coordinated purchasing, and reliable demand forecasts can help public health programmes use resources efficiently.

Stronger health systems: Investment in cold-chain equipment, trained staff, data systems, and community outreach can improve vaccination coverage and reduce wastage.

Economic evaluation: Governments can use local disease burden, programme costs, and health outcomes to prioritise vaccines according to public health needs.

These developments could make vaccination programmes more sustainable, but their actual benefits depend on implementation, financing, and the evidence available for each vaccine.

Conclusion: Vaccination is both a health decision and an economic decision

The economics of vaccines is not simply a debate about pharmaceutical profits or the price of a dose.

It is about how society allocates limited resources to prevent disease, protect vulnerable people, support economic productivity, and maintain a resilient healthcare system.

A sound vaccination policy must balance affordability, safety, effectiveness, fair access, and financial sustainability.

Governments should seek value for public money. Manufacturers should meet high standards of quality and transparency. Healthcare professionals should communicate benefits and risks honestly. Researchers should continue evaluating real-world outcomes.

Ultimately, the most useful question is not merely, “How much does this vaccine cost?”

It is:

“What health benefits does this vaccine deliver, at what total cost, and who gets to benefit?”

That is the foundation of evidence-based vaccine economics.

Suggested sources for further reading

Disclaimer: This article is for general education and does not replace professional economic, financial, or medical advice. Vaccine prices, procurement arrangements, and cost-effectiveness vary by country, programme, and year.


COVID Vaccine and Heart Attack: What Should Indians Know About Covishield, Covaxin and Long-Term Health Risks?

 


COVID Vaccine and Heart Attack: What Should Indians Know About Covishield, Covaxin and Long-Term Health Risks?

A science-based guide to COVID-19 vaccines, heart attacks, blood clots and other health concerns

Introduction: A question that still worries millions

Years after the COVID-19 vaccination campaign, one question continues to concern many families:

Can COVID-19 vaccines cause heart attacks or other serious diseases years later?

In India, millions of people received Covishield or Covaxin. Both vaccines played an important role during the pandemic, helping protect people against severe COVID-19. However, like all medical interventions, they also had potential side effects, including some rare but serious complications.

The answer is neither to dismiss every concern nor to blame every illness on vaccination. The responsible approach is to examine scientific evidence, understand genuine risks and distinguish confirmed adverse effects from claims that have not been established.

Let's explore what the medical evidence tells us.

1. Covishield and Covaxin: Understanding the difference

Although both vaccines were developed to protect against COVID-19, they used different technologies.

Covishield

Covishield uses a modified, non-replicating adenovirus to deliver instructions that help the body recognise the coronavirus spike protein. It is based on the technology developed for the Oxford–AstraZeneca vaccine.

A rare but serious complication associated with this vaccine is thrombosis with thrombocytopenia syndrome (TTS), in which unusual blood clots develop alongside a low platelet count. This complication was recognised by health authorities and requires appropriate medical attention. 11

Covaxin

Covaxin uses an inactivated form of the coronavirus. Because the virus has been inactivated, it cannot reproduce and cause COVID-19.

Both vaccines can cause temporary reactions such as pain at the injection site, fever, headache and fatigue. Serious reactions are much less common.

2. Does the COVID vaccine cause heart attacks?

This is one of the most important questions to answer accurately.

A heart attack usually occurs when blood flow to part of the heart muscle becomes blocked, commonly because of coronary artery disease and a blood clot forming over a disrupted plaque.

Several factors can increase heart attack risk, including:

  • High blood pressure

  • Diabetes

  • High cholesterol

  • Smoking and tobacco use

  • Obesity and physical inactivity

  • Family history and increasing age

  • Certain inflammatory illnesses, including COVID-19

A heart attack occurring after vaccination does not automatically mean the vaccine caused it. Doctors and researchers must consider the timing, the person's medical history, possible alternative explanations and evidence of a recognised vaccine-related complication.

What does the evidence say?

There is no convincing evidence that Covishield or Covaxin causes a widespread, long-term increase in heart attacks across the general population.

However, that does not mean every possible adverse reaction can be ruled out. Rare complications and individual cases need careful assessment. Indian studies examining reported serious adverse events have found that many events were considered coincidental or could not be definitively attributed to vaccination. 22

The key distinction is between an event that happened after vaccination and an event that happened because of vaccination.

3. Covishield and blood clots: What is the real risk?

One vaccine-related complication deserves particular attention.

TTS, sometimes called vaccine-induced immune thrombotic thrombocytopenia (VITT), involves abnormal blood clotting together with low platelet levels. It was associated with certain adenovirus-vector COVID-19 vaccines, including Covishield.

It is a rare but potentially life-threatening condition. The risk was recognised during the vaccination programme, and medical authorities advised clinicians to watch for characteristic symptoms following vaccination. 11

Symptoms associated with this complication can include:

  • A severe or persistent headache

  • Severe abdominal pain

  • Shortness of breath

  • Leg swelling or persistent leg pain

  • Neurological symptoms or unusual bruising

These symptoms are especially concerning when they develop in the days following vaccination, within the recognised period of risk.

What about people vaccinated several years ago?

TTS associated with these vaccines generally appeared within days to a few weeks after vaccination. It is not the same as ordinary coronary artery disease, and it should not be assumed that someone who received Covishield years ago remains at high risk of developing TTS today.

A current heart or circulation problem should be investigated on its own medical merits rather than automatically attributed to a past vaccine.

4. Can COVID vaccines cause other diseases?

This question requires us to distinguish recognised adverse effects from unproven claims.

Heart inflammation

Myocarditis is inflammation of the heart muscle, while pericarditis is inflammation of the surrounding membrane.

These conditions have been associated most clearly with certain mRNA vaccines, particularly in adolescent and young adult males. They are distinct from a typical heart attack.

They should not be automatically attributed to Covishield or Covaxin, which use different vaccine technologies.

Neurological complications

Rare neurological adverse events have been reported following some COVID-19 vaccines. Guillain–Barré syndrome, a condition affecting peripheral nerves, has been associated with certain adenovirus-vector vaccines.

However, a neurological illness developing after vaccination does not establish causation. Medical evaluation and appropriate investigation are essential.

Blood disorders

Rare immune-mediated blood-clotting disorders, including TTS, were recognised after Covishield and certain related vaccines.

Other changes in blood counts or bleeding symptoms require individual evaluation. The presence of a symptom alone cannot establish that vaccination was responsible.

Diabetes, cancer, kidney disease and other chronic illnesses

There is no established evidence that Covishield or Covaxin causes a general epidemic of diabetes, cancer, kidney failure or other chronic diseases years after vaccination.

These illnesses have multiple causes, including genetics, ageing, environmental exposures, infections and lifestyle factors. Some may also be influenced by the effects of COVID-19 itself.

Claims that vaccines are responsible for every new diagnosis are not supported by reliable scientific evidence.

5. Could COVID-19 infection itself affect the heart?

Yes. This is an important part of the discussion.

COVID-19 can affect the cardiovascular system through inflammation, changes in blood clotting, damage to blood vessels and increased stress on the heart. Some people experience cardiovascular complications during or after infection.

Severe infection can also place additional strain on people who already have diabetes, hypertension or heart disease.

This is why an investigation into a heart attack or other illness should consider previous COVID-19 infection, existing health conditions, lifestyle factors and other relevant causes, alongside vaccination history.

A balanced assessment must consider both the risks of infection and the potential adverse effects of vaccination.

6. Why are heart attacks being reported in younger people?

Reports of heart attacks among younger adults are understandably worrying. But individual news stories and social media posts cannot tell us whether the overall rate has increased or what caused any change.

To answer that question, researchers need reliable population data, comparisons with previous years, age-specific statistics and information about risk factors.

Possible contributors to cardiovascular disease include:

  • Undiagnosed high blood pressure or diabetes

  • High cholesterol

  • Smoking, tobacco and other substance use

  • Poor sleep and chronic stress

  • Physical inactivity and obesity

  • Genetic predisposition

  • Previous COVID-19 infection and its complications

These factors do not explain every individual case. Equally, the timing of vaccination alone cannot establish that the vaccine was responsible.

The right response is better data, medical investigation and prevention—not fear or premature conclusions.

7. What should people who received Covishield or Covaxin do now?

If you received either vaccine and feel well, there is no evidence-based reason to assume that you will develop a heart attack or another serious disease simply because you were vaccinated.

Instead, focus on measures that reduce established health risks.

Practical steps for protecting your heart:

  1. Check your blood pressure regularly.

  2. Screen for diabetes and high cholesterol as recommended for your age and risk profile.

  3. Avoid smoking and tobacco.

  4. Maintain regular physical activity, a balanced diet and healthy sleep habits.

  5. Seek medical advice for persistent or unexplained symptoms.

  6. Tell your doctor about your vaccination and COVID-19 infection history when discussing a relevant medical problem.

Routine cardiac tests are not necessary for every healthy person solely because they received a COVID-19 vaccine. Testing should be guided by symptoms, medical history and a clinician's assessment.

Never ignore emergency symptoms. Chest pressure or pain, sudden breathlessness, cold sweating, fainting or pain spreading to the arm, jaw or back can indicate a heart attack. Seek emergency medical care immediately rather than waiting for symptoms to settle.

8. The conclusion: Follow evidence, not fear

COVID-19 vaccines were developed during an extraordinary public health emergency. They helped protect many people against severe disease, while post-vaccination monitoring also identified rare adverse effects that deserved attention.

Both facts can be true at the same time.

Covishield has a recognised association with a rare clotting disorder involving low platelets. Some other COVID-19 vaccines have different, specific safety concerns. But the evidence does not justify claiming that Covishield or Covaxin causes widespread heart attacks or a broad range of chronic diseases years later.

Scientific understanding continues to develop, and individual medical problems deserve careful investigation.

The most important message is simple:

Do not ignore genuine symptoms. Do not assume every illness is vaccine-related. And do not let unverified social media claims replace sound medical advice.

Our health decisions should be guided by evidence, transparency and compassionate medical care—not panic.

References and further reading

  1. World Health Organization. Global Advisory Committee on Vaccine Safety review of rare adverse blood coagulation events with AstraZeneca COVID-19 vaccine, including Covishield.
    https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-%28gacvs%29-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine

  2. Serious adverse event following immunization and thromboembolic events associated with COVID-19 vaccination: An analysis of nationwide causality assessment from India.
    https://pubmed.ncbi.nlm.nih.gov/36863611/

  3. Ministry of Health and Family Welfare, Government of India. National AEFI Surveillance and Response Operational Guidelines, 2024.
    https://mohfw.gov.in/sites/default/files/National%20AEFI%20Surveillance%20and%20Response%20Operational%20Guidelines%202024_0.pdf


Wednesday, October 14, 2026

Can Artificial Intelligence Clean Up Healthcare Corruption? From Suspicion to Systemic Accountability

 


Can Artificial Intelligence Clean Up Healthcare Corruption? From Suspicion to Systemic Accountability

How AI could help India detect medical fraud, expose procurement irregularities, prevent insurance abuse and protect public money — provided the technology itself remains transparent and accountable.

Introduction: When Healthcare Corruption Becomes a Patient Safety Issue

Healthcare corruption is not merely a financial crime. It is a direct threat to human life.

When medicines are purchased at inflated prices, when substandard medical equipment enters hospitals, when insurance claims are raised for treatments that never occurred, or when public funds disappear through manipulated contracts, the consequences extend far beyond government accounts. Patients may face treatment delays, hospitals may experience shortages, and families may be forced to pay out of pocket for services that should have been available to them.

India's healthcare system operates at an enormous scale, involving government hospitals, private providers, pharmaceutical companies, insurers, Third-Party Administrators (TPAs), diagnostic centres and public health schemes. Every connection between these stakeholders creates an opportunity for efficiency — but also a potential vulnerability to fraud.

Recent allegations concerning medical procurement in Delhi have brought these vulnerabilities into focus. Investigations reported in 2026 have examined alleged irregularities in the purchase of medicines, surgical supplies and medical equipment worth hundreds of crores. These remain matters for investigation and due process, not a basis for presuming the guilt of every person or institution involved. Nevertheless, they raise an important question: could better technology have helped identify suspicious transactions earlier? Source: The Indian Express, September 2026.

Artificial intelligence (AI) offers a promising part of the answer.

AI cannot guarantee a corruption-free healthcare system. But it can make suspicious patterns harder to hide, financial transactions easier to trace, and oversight more continuous than traditional manual audits often allow.

The real opportunity is not to replace human accountability with algorithms. It is to build a healthcare system in which wrongdoing is more difficult to commit, easier to detect and harder to conceal.

1. Why Traditional Healthcare Oversight Is Not Enough

Healthcare corruption rarely occurs through a single transaction that immediately appears suspicious. It may develop through a chain of individually plausible decisions.

A supplier may quote a slightly inflated price. A tender may contain restrictive specifications. A hospital may repeatedly purchase from the same vendor. A stock register may show medicines as received even when physical inventory tells a different story. An insurance claim may look legitimate until it is compared with hundreds of similar claims.

Traditional auditing is essential, but it often relies on sample checks, documentation reviews and investigations conducted after a problem has been reported. When records are fragmented across departments and institutions, connecting the dots becomes difficult.

Three structural weaknesses make this challenge particularly significant:

  • Fragmented data: Procurement, inventory, billing, insurance and patient records may sit in separate systems.

  • Delayed detection: Irregularities may only become visible months after payments have been made.

  • Limited audit capacity: Human auditors cannot manually examine every transaction in a large healthcare network in real time.

AI can help address these weaknesses by analysing large volumes of structured and unstructured data, identifying unusual patterns and directing investigators towards transactions that deserve closer scrutiny.

The distinction is important: AI does not automatically prove fraud. It helps identify where a closer examination may be necessary.

2. AI in Medical Procurement: Following the Money

Public procurement is one of the most promising areas for AI-enabled oversight.

Government healthcare institutions purchase medicines, surgical consumables, diagnostic equipment, hospital furniture, laboratory supplies and a wide range of services. Small pricing differences across thousands of transactions can add up to substantial expenditure.

An AI-enabled procurement monitoring system could analyse:

  • Prices paid by different hospitals for comparable products.

  • Differences between quoted prices and historical purchase prices.

  • Repeated awards to the same supplier or connected vendors.

  • Unusually short tender periods or suspicious bidding patterns.

  • Changes in quantities after a contract has been awarded.

  • Repeated emergency purchases that bypass ordinary planning.

  • Invoices that do not match purchase orders, delivery records or stock receipts.

For example, imagine that several hospitals purchase the same standard medical consumable. Most pay approximately ₹100 per unit, while one hospital repeatedly pays ₹180 to the same supplier.

That difference is not proof of corruption. Product specifications, quality, transport costs, taxes, contract terms and local supply conditions may explain it. But an AI system could flag the difference, compare the relevant records and send the transaction for review.

A more advanced system could connect tender documents, vendor ownership information, invoices, electronic delivery confirmations and payment records. It could then identify relationships that might be difficult to detect when each document is reviewed independently.

The objective is straightforward: move procurement oversight from occasional retrospective checking towards continuous risk-based monitoring.

However, the quality of the results depends on reliable data. If product descriptions are inconsistent, vendor identities are duplicated or procurement records are incomplete, the system may produce misleading alerts. AI must therefore be supported by standardised product codes, verified supplier records and a dependable digital audit trail.

3. AI and Health Insurance: Detecting Claims That Do Not Add Up

Insurance fraud creates another important opportunity for AI.

India's health insurance ecosystem includes private insurers, TPAs, hospitals and publicly funded programmes. Claims must be assessed for eligibility, documentation, medical necessity and compliance with applicable policy or scheme rules.

Potential irregularities can include duplicate billing, repeated claims for the same service, billing for services that were not provided, suspicious treatment patterns and inconsistencies between clinical documentation and claimed procedures.

AI can screen claims for patterns such as:

  • Multiple claims that appear to relate to the same treatment episode.

  • Unusually high volumes of particular procedures at a facility.

  • Repeated billing patterns that differ significantly from comparable providers.

  • Inconsistencies between discharge summaries, procedure records and invoices.

  • Potentially altered, duplicated or fabricated supporting documents.

  • Unexpected relationships between providers, patients and billing entities.

This is especially valuable when claims are processed at scale. A human reviewer may struggle to identify a pattern spread across thousands of records, while an appropriately designed analytical system can compare them rapidly.

India is already exploring this direction. In May 2026, the National Health Authority, working with the IndiaAI Mission and the Indian Institute of Science, showcased solutions developed through the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) Auto-Adjudication Hackathon. The initiative included AI-based clinical document analysis and forgery or deepfake detection, with an emphasis on improving transparency and claims integrity. This is an encouraging step towards AI-assisted oversight, although a hackathon showcase should not be mistaken for proof that every solution has been deployed nationwide or has already reduced fraud. Source: Press Information Bureau, 9 May 2026.

The policy implication is significant. Rather than relying exclusively on random audits or complaints, health schemes could use AI to prioritise claims for review according to risk.

But a high-risk score must not become an automatic declaration of guilt. A complex but legitimate case can look unusual. A hospital treating a large number of seriously ill patients may naturally have a different claims profile from a smaller facility.

AI should help investigators ask better questions — not make unchallengeable decisions about patients or providers.

4. Can AI Help Detect Ghost Patients and Unnecessary Procedures?

A further challenge involves services that may have been billed but not genuinely delivered.

In some healthcare fraud scenarios, claims may be submitted for non-existent patients, duplicated patient identities, treatments that were not performed or services that were not medically justified. AI can help identify patterns across patient registration, admission, procedure, pharmacy and discharge records.

For example, a system could flag repeated use of the same patient identifier across incompatible admissions, unusual clusters of claims, or billing records that do not align with the documented treatment timeline.

Where appropriate, these signals could be cross-checked against authenticated records and independently verified evidence.

Yet this area requires particular care. Medical records contain sensitive personal information, and unusual treatment patterns can have legitimate explanations. A patient may seek care at multiple hospitals, and a complicated illness may involve several procedures or specialists.

Any use of AI to detect suspicious treatment activity must therefore include strict privacy protections, access controls and a process for correcting inaccurate records. Data should be used only for legitimate, clearly defined purposes.

The goal must be to protect patients and public funds — not to create a system in which patients are treated as suspects because an algorithm cannot understand their circumstances.

5. Medicine Stock Management: Reducing Leakage and Shortages

Corruption is not always visible as an inflated invoice. It can also appear as a gap between what a hospital purchases, what it receives and what it actually has available for patients.

AI-enabled inventory systems could compare procurement orders with delivery records, batch numbers, expiry dates, dispensing logs and physical stock verification.

Such systems could flag:

  • Stock levels that are inconsistent with recorded purchases and consumption.

  • Repeated shortages despite apparently adequate supplies.

  • Unexplained losses of high-value medicines.

  • Unusually high wastage or expiry rates.

  • Sudden changes in consumption that require verification.

  • Repeated discrepancies between electronic records and physical counts.

Predictive analytics can also forecast demand and help hospitals order appropriate quantities. Better forecasting may reduce emergency purchases, overstocking and avoidable medicine expiry.

This creates a useful connection between operational efficiency and anti-corruption efforts. A hospital that knows what it ordered, what arrived, where it was stored and when it was dispensed has a stronger basis for detecting discrepancies.

Still, a digital inventory record is not the same as a verified physical stock. If a person enters false information into the system, AI may analyse that information very efficiently without discovering the underlying deception. Periodic physical verification, supplier confirmation and clear responsibility for stock handling remain essential.

6. The TPA Opportunity: Moving from Claims Processing to Intelligent Oversight

Third-Party Administrators have an important role in the health insurance ecosystem. They commonly support activities such as cashless authorisation, claims processing, documentation review and coordination between hospitals and insurers, depending on their contractual responsibilities.

AI could help TPAs and insurers identify unusual billing patterns, duplicate documentation, inconsistent coding and claims that warrant medical audit.

For example, an AI system could compare a hospital's claims profile with its own historical data and with appropriately adjusted peer benchmarks. If the frequency or cost of a particular procedure rises sharply, the system could flag the change for review.

It could also help organise large volumes of medical documents, identify missing records and direct complex claims to appropriately qualified reviewers.

However, the incentives matter. If an AI system is designed primarily to reject expensive claims or reduce payouts, it could unfairly disadvantage patients with complex conditions. Likewise, if hospitals or insurers can influence the model without independent oversight, the system could reinforce existing conflicts of interest.

A responsible framework should require clear rules for claim review, documented reasons for adverse decisions, human reconsideration and a meaningful appeal mechanism.

The objective should be to detect fraudulent claims without making legitimate healthcare harder to access.

7. The Biggest Risk: What If AI Becomes Another Tool for Corruption?

It would be a mistake to assume that technology automatically creates transparency.

AI systems are developed, purchased, configured and operated by people and organisations. If those processes are not transparent, the technology may introduce new risks.

Consider four possibilities.

First, manipulated data. If procurement records are deliberately falsified, an AI system may produce misleading conclusions.

Second, biased algorithms. If historical data contains unfair patterns, the model may disproportionately flag certain hospitals or providers without sufficient justification.

Third, opaque decisions. If officials cannot explain why a transaction was flagged or cleared, it becomes difficult to challenge errors or assign responsibility.

Fourth, conflicts of interest. If the organisation being monitored controls the system's data, settings or audit access, it may be able to weaken the very oversight the technology is meant to provide.

There is also a danger that AI could be used to create the appearance of compliance: dashboards may look sophisticated while key records remain missing, exceptions go unexplained and audit findings lead to no action.

For these reasons, AI systems used in public healthcare must themselves be auditable. Their performance should be tested, access to sensitive data controlled, material changes documented and significant decisions subject to human review.

India's governance approach recognises the importance of responsible and trusted AI. The India AI Governance Guidelines emphasise balancing innovation with safety, accountability and inclusion. These principles are relevant not only to clinical AI but also to systems used for procurement, insurance and public administration. Source: Press Information Bureaucracy, February 2026.

8. What India Should Do Next

If India wants AI to become a credible tool against healthcare corruption, implementation should focus on governance rather than technology alone.

1. Build an integrated, traceable procurement system

Standardise product descriptions, supplier identities, tender records, purchase orders, delivery confirmations, invoices and payments. Link these records wherever legally and operationally appropriate.

2. Establish continuous risk-based audits

Use AI to identify unusual prices, repeated vendor concentration, duplicate payments and unexplained stock discrepancies. Every alert should have a defined review process and a recorded outcome.

3. Keep an independent human decision-maker in the loop

AI should flag risks and organise evidence. Authorised professionals should investigate, consider explanations and make consequential decisions in accordance with the law.

4. Create public transparency without compromising privacy

Publish appropriate procurement information, contract awards, aggregate spending, audit findings and action-taken reports. Patient-identifiable information and legitimate confidential data must remain protected.

5. Audit the AI system itself

Independently assess accuracy, false positives, missed cases, bias, security and the possibility of manipulation. Maintain records of who changed the system, why it was changed and how those changes affected results.

6. Protect whistle-blowers and strengthen accountability

Technology cannot replace people who report wrongdoing. Staff, suppliers and healthcare professionals need safe, credible channels to raise concerns, along with fair procedures for investigating them.

7. Measure results, not software adoption

Success should be judged by outcomes: fewer unexplained price differences, more accurate inventory, shorter investigation delays, better recovery of misused funds, fairer claims processing and improved availability of medicines and services.

The most important performance indicator is not how many transactions an AI system flags. It is how effectively the healthcare system verifies those alerts, corrects genuine problems and prevents recurrence.

Conclusion: AI Can Illuminate the System, but People Must Act

Can artificial intelligence clear corruption from healthcare?

Not by itself.

AI cannot replace ethical leadership, honest procurement officers, competent auditors, independent investigators or a justice system that acts on credible evidence. Nor can it guarantee that the information fed into a digital system is truthful.

What it can do is make large and complicated healthcare systems more observable. It can compare transactions that would otherwise remain disconnected, identify unusual patterns earlier, strengthen documentation and help oversight teams focus their limited resources where they may matter most.

For India, the opportunity is especially important because public healthcare spending must translate into medicines, equipment, treatment and better patient outcomes. Every rupee diverted through proven fraud is a rupee that cannot serve its intended purpose.

The path forward is therefore not simply to introduce AI into hospitals and government departments. It is to combine reliable digital records, intelligent risk detection, independent audits, transparent procurement, privacy safeguards and enforceable accountability.

AI may not eliminate corruption, but it can help build a system in which corruption is harder to conceal and public money is easier to trace.

Ultimately, the success of AI in healthcare will not be measured by the sophistication of its algorithms. It will be measured by whether patients receive the care they need, hospitals receive the supplies they were promised, and public money reaches the purpose for which it was allocated.


Corruption in Healthcare: What Recent Events in Delhi Reveal About Governance, Public Money and Patient Welfare

 


Corruption in Healthcare: What Recent Events in Delhi Reveal About Governance, Public Money and Patient Welfare

A healthcare economics perspective on procurement irregularities, accountability and the human cost of corruption


Introduction: When corruption enters the healthcare system, patients pay the price

Healthcare corruption is often discussed in terms of money lost, officials investigated or contracts allegedly manipulated. But these measures tell only part of the story.

When public money intended for hospitals is allegedly lost through inflated procurement prices, the consequences can extend far beyond government accounts. Hospitals may receive fewer supplies for the same budget. Equipment investments may deliver less value. Administrative failures can undermine service delivery, and patients may ultimately bear the cost through delayed treatment, unavailable medicines or reduced confidence in public institutions.

Recent developments in Delhi have brought these questions into sharp focus.

In 2026, the Delhi government's health procurement system became the subject of a major Anti-Corruption Branch investigation involving alleged irregularities in the purchase of medicines, surgical supplies and medical equipment. Separately, allegations concerning hospital construction projects, concerns about staffing and a reported disappearance of expensive cancer medicines have highlighted different dimensions of governance in public healthcare.

These matters are not all the same, and they should not be treated as proof of one common conspiracy. Some involve criminal allegations under investigation, others concern administrative or judicial scrutiny, and some raise operational concerns that are not, by themselves, evidence of corruption.

Nevertheless, together they raise an important question for healthcare leaders and policymakers:

How can a healthcare system protect public money while ensuring that every rupee allocated to patient care delivers genuine clinical and social value?

The answer requires more than arrests, inquiries or changes in government. It requires transparent procurement, strong internal controls, independent oversight and a governance model that treats patient welfare as the ultimate measure of public expenditure.

1. Delhi's alleged medical procurement scam: Understanding the economics

One of the most significant recent cases concerns alleged irregularities in procurement through the Central Procurement Agency (CPA), which supplies medicines, surgical items and medical equipment to Delhi government healthcare facilities.

According to reporting by The Indian Express and India Today in June 2026, the Anti-Corruption Branch registered a case following allegations that procurement prices were substantially inflated and that tender processes had been manipulated to favour selected suppliers.

The reported allegations included discrepancies involving portable X-ray machines, C-arm equipment, hospital linen, oral rehydration salts and surgical supplies. The reported estimates of potential losses and the overall scale of the case have varied across accounts. The investigation, rather than a final judicial determination, must establish the facts.

Sources:

Why does procurement matter so much in healthcare?

Procurement is not merely an administrative activity. It is one of the most important financial functions in a healthcare organisation.

Hospitals require medicines, diagnostic equipment, surgical instruments, consumables, linen, laboratory supplies and maintenance services. Every procurement decision affects the cost, availability and quality of healthcare delivery.

Consider a simplified illustration.

A government hospital has a budget of ₹10 crore for medical equipment. If the hospital can obtain equipment that meets the required clinical specifications at competitive prices, the budget may support a larger number of departments or facilities.

If the same equipment is purchased at unjustifiably inflated prices, the hospital may receive fewer units for the same expenditure.

The result is an opportunity cost: money spent inefficiently cannot simultaneously be used to meet other healthcare needs.

This does not mean the cheapest product is always the best purchase. Medical equipment must be assessed on quality, safety, warranty, maintenance, compatibility, training and lifecycle costs.

The objective is the best defensible value for public money, not simply the lowest purchase price.

What makes alleged procurement manipulation particularly damaging?

If an investigation establishes that prices were deliberately inflated, tender conditions manipulated or payments improperly approved, the damage can occur at several levels:

  • Public funds may be diverted from their intended purpose.

  • Competitive suppliers may be excluded.

  • Hospitals may receive fewer supplies than their budgets should support.

  • Equipment quality and maintenance may receive insufficient attention.

  • Public officials and legitimate suppliers may lose confidence in procurement systems.

The economic harm is not limited to the alleged financial loss. It also includes the value of healthcare services that the same money could otherwise have supported.

2. The human cost: Public money is ultimately meant for patients

It is easy to discuss an alleged procurement irregularity as a financial dispute between government departments and suppliers.

Healthcare economics demands a different perspective.

The real question is what that expenditure was intended to achieve.

A portable X-ray machine is meant to support diagnosis. Surgical supplies are intended to enable safe procedures. Medicines are necessary for treatment. Hospital beds and linen contribute to the functioning of clinical services.

When procurement systems fail, the immediate financial loss may be measurable, but the full patient impact can be more difficult to quantify.

For example, a hospital that cannot obtain sufficient equipment may have to redirect patients, delay certain investigations or rely on alternative facilities. Whether those outcomes actually occurred in a particular case must be established using hospital-level evidence rather than assumed from the existence of an investigation.

The broader principle, however, is clear: procurement governance and clinical outcomes are closely connected.

A healthcare budget should therefore be evaluated using two complementary measures:

  1. Financial integrity: Was the money spent lawfully, transparently and at a defensible price?

  2. Clinical value: Did the expenditure deliver the required healthcare capacity, quality and patient benefit?

A system that examines only the first measure may overlook whether equipment is actually used. A system that examines only the second may overlook waste, inflated costs or improper conduct.

Both matter.

3. What happened after the allegations emerged?

The response to Delhi's procurement case also offers an important lesson about the design of public healthcare administration.

In August 2026, The Indian Express reported that Delhi's Health Department had temporarily put centralised procurement through the CPA on hold for most categories covered by the order, allowing individual government hospitals to undertake specified purchases under the applicable rules. Existing arrangements were subject to the conditions outlined in the order.

The stated purpose included maintaining the uninterrupted availability of essential healthcare supplies while procurement arrangements were reviewed.

Source: The Indian Express, August 7, 2026.

This development highlights a difficult administrative trade-off.

Centralised procurement can aggregate demand, improve bargaining power, standardise specifications and reduce duplicated purchasing work. It can also concentrate decision-making and create a large point of vulnerability if controls fail.

Decentralised procurement can allow hospitals to respond to local needs and make certain purchases more quickly. However, it can also fragment demand, reduce negotiating leverage and make oversight more complicated if many institutions use different processes.

Neither model is inherently immune to corruption.

The appropriate question is not simply whether procurement should be centralised or decentralised. It is how the system should distribute authority, verify prices, document decisions and detect irregularities before significant public funds are committed.

A robust model may combine centralised price discovery and common technical standards with clearly defined local purchasing authority, subject to transparent rules and independent audit.

4. Accountability: Investigations must establish responsibility, not merely generate headlines

By September 30, 2026, The Indian Express reported that the Delhi government had sanctioned prosecution of three former officials in connection with the alleged procurement scam. The report also described allegations concerning tendering, supplier relationships and the processing of payments.

The same date, separate reporting by the newspaper said a court had flagged investigative lapses, including concerns about entries in a case diary and undated statements.

Sources:

These developments must be read together.

Sanction for prosecution is a significant procedural step, but it is not a conviction. Arrest, an FIR or a chargesheet does not by itself establish guilt. Equally, concerns about the quality of an investigation do not automatically disprove the underlying allegations.

A credible anti-corruption framework must allow allegations to be investigated thoroughly, evidence to be tested and responsibility to be established through due process.

Why does this matter economically?

Because weak accountability has two costs.

First, failure to investigate genuine misconduct can allow waste and improper practices to continue. Second, poorly conducted investigations can undermine legitimate enforcement, damage reputations unfairly and make it harder to establish the truth.

The objective should be reliable accountability, not simply visible action.

For healthcare institutions, this means clearly defined responsibilities, documented approvals, audit trails, independent review and consequences based on established findings.

5. Hospital construction controversies: The opportunity cost of unfinished infrastructure

The procurement investigation is not the only issue that has raised questions about healthcare governance in Delhi.

In June 2025, the Anti-Corruption Branch registered an FIR concerning alleged irregularities and delays in government hospital, polyclinic and intensive care infrastructure projects. The case involved projects sanctioned under earlier administrations, and former health ministers were named in the reported FIR.

The allegations included cost escalations, missed deadlines and questions about the implementation of planned healthcare facilities. The accused and their political representatives disputed aspects of the allegations. The registration of the FIR should not be interpreted as proof that the named individuals committed an offence.

Source: The Indian Express, June 26, 2025.

From a healthcare economics perspective, the most important issue is the value of infrastructure investment.

A hospital project does not create full healthcare capacity simply because money has been spent on construction.

It must be completed, equipped, staffed, supplied and integrated into the healthcare network. A building without adequate clinical personnel or functional equipment cannot provide the intended level of care.

The economics of delayed projects

Delays can generate several types of cost:

  • Escalation in construction and material costs.

  • Additional financing and administrative expenditure.

  • Deferred access to planned medical services.

  • Potential deterioration or underutilisation of completed assets.

  • Lost opportunities to reduce pressure on existing hospitals.

The extent of these costs varies by project and requires documentary evidence.

Nevertheless, one principle should guide public infrastructure investment: expenditure incurred is not the same as public value delivered.

A project should be monitored from sanction through design, construction, commissioning, staffing and actual service delivery. Milestones should be independently verified, and changes in cost or timelines should require documented justification.

6. The reported disappearance of cancer medicines: A different but related governance question

A separate report published by The Indian Express on October 14, 2026, said that four vials of nimotuzumab, a costly medicine used in certain cancer treatments, had reportedly gone missing from the Delhi State Cancer Institute. The report also referred to a missing hepatitis C medicine and stated that a police investigation was underway.

Source: The Indian Express, October 14, 2026: Cancer medicines reported missing from Delhi hospital.

At the time of that report, the circumstances and responsibility had not been established. A reported loss of medicines is not, by itself, proof of corruption or organised theft.

Nevertheless, the incident raises an important governance question: how should hospitals control high-value and clinically essential medicines?

Medicines require more than a purchasing system. They also require secure receipt, appropriate storage, inventory reconciliation, authorised dispensing, documentation and monitoring of stock movements.

For high-value medicines, practical controls can include:

  • Batch-level inventory records.

  • Restricted access to storage facilities.

  • Electronic recording of receipt and dispensing.

  • Regular reconciliation of physical and recorded stock.

  • Documented investigation of discrepancies.

  • Clear separation of ordering, receiving and stock-approval responsibilities.

Such controls protect public resources while helping ensure that medicines remain available to patients who need them.

The objective is not to assume wrongdoing whenever a discrepancy occurs. It is to ensure that every discrepancy can be explained, investigated and resolved through a reliable process.

7. Corruption versus administrative failure: Why the distinction matters

Not every healthcare failure is corruption.

A hospital may experience delays because of poor planning, inadequate staffing, weak coordination, insufficient funding, technical problems or slow approvals. Corruption involves a different set of concerns, such as bribery, dishonest manipulation, improper personal benefit or other unlawful conduct, depending on the evidence and applicable law.

These problems can overlap, but they should not be treated as interchangeable.

For example:

  • A delayed procurement process may indicate administrative inefficiency; evidence of deliberate favouritism or bribery would require a separate assessment.

  • A missing medicine may reflect an inventory error, a documentation failure or theft. Investigation is needed to establish what happened.

  • An incomplete hospital project may result from contractual disputes, planning failures, inadequate execution or alleged misconduct.

  • A high purchase price may reflect specialised specifications or lifecycle costs, or it may indicate an unjustified premium. A proper comparison requires like-for-like evidence.

This distinction is essential for two reasons.

First, it prevents public debate from turning unverified allegations into established facts. Second, it allows governments and healthcare organisations to address the actual cause of a failure rather than relying on a single response to every problem.

Anti-corruption enforcement is necessary where wrongdoing is suspected. Better management, stronger controls and more capable institutions are equally necessary to prevent failures that arise from other causes.

8. The systemic vulnerabilities that healthcare procurement must address

The Delhi cases raise questions that are relevant well beyond one city or administration.

A. Tender design and competition

Specifications should be based on genuine clinical requirements. Unnecessarily restrictive criteria can reduce competition, while poorly designed tenders may result in unsuitable products or weak service support.

Tender documents should clearly state technical requirements, evaluation criteria, delivery obligations and maintenance responsibilities.

B. Price benchmarking

Public buyers need reliable comparisons with equivalent products and services. Comparisons should account for specifications, quantities, warranties, delivery terms, maintenance and other relevant costs.

Large price differences should trigger documented scrutiny, not automatic conclusions of wrongdoing.

C. Separation of responsibilities

No single individual should exercise unchecked control over the entire procurement process.

Requesting a product, defining specifications, evaluating bids, approving expenditure, receiving supplies and authorising payment should involve appropriate checks and independent verification.

D. Supplier due diligence

Buyers should verify supplier credentials, beneficial ownership where required, technical capacity, financial standing, conflicts of interest and performance history.

Appropriate due diligence helps reduce the risk of collusion, non-performance and conflicts of interest.

E. Contract and delivery verification

The purchase order is only one stage of procurement. Hospitals must verify that the correct quantity and quality of supplies have been delivered and that equipment performs as specified.

Payment approval should follow the applicable verification and acceptance procedures.

F. Independent audit and whistle-blower protection

Internal controls should be supplemented by independent financial and technical audits. Employees who identify irregularities need credible reporting channels and protection against retaliation under applicable law and policy.

These measures can help identify weaknesses before they become major financial or operational failures.

9. What should Delhi—and India—do differently?

A meaningful response should go beyond suspending a procurement process or investigating individual officials. It should strengthen the systems that govern healthcare expenditure.

1. Build a transparent procurement dashboard

For major public healthcare purchases, governments should publish appropriate information on tender specifications, bidders, award values, delivery milestones and contract performance, subject to lawful confidentiality and security restrictions.

Transparency makes it easier for auditors, suppliers, researchers and citizens to identify unusual patterns.

2. Use independent price and technical verification

Large or high-risk purchases should undergo independent scrutiny of technical specifications, comparable market prices and total lifecycle costs.

The review should be proportionate to the size, complexity and risk of the purchase.

3. Create end-to-end digital audit trails

Every major decision—from requisition and tender evaluation to delivery and payment—should be traceable.

Digital systems cannot eliminate collusion on their own, but they can make undocumented changes and unexplained approvals more difficult to conceal.

4. Measure whether purchased assets actually improve care

Governments should track not only procurement expenditure but also equipment installation, uptime, utilisation, maintenance, availability of trained operators and the services delivered.

A machine that has been purchased but remains unusable represents a different kind of value failure from an inflated purchase price. Both deserve attention.

5. Strengthen inventory management

Hospitals should maintain reliable records for medicines, surgical supplies and high-value equipment, with risk-based physical verification and documented resolution of discrepancies.

6. Protect continuity of healthcare services

When procurement arrangements are suspended or restructured, governments must ensure that essential medicines and supplies remain available.

Reforms should be designed so that the effort to improve accountability does not unintentionally disrupt patient care.

7. Make responsibility measurable

Senior administrators, procurement officers, technical evaluators, finance personnel and contractors should have clearly defined duties.

Accountability should be based on documented responsibilities, evidence and due process—not merely the seniority or political position of an individual.

8. Publish corrective actions and follow-up outcomes

After an audit or investigation identifies a weakness, institutions should document the corrective action, responsible authority, implementation timeline and subsequent verification.

The public interest is served when investigations lead to stronger systems as well as appropriate legal consequences where misconduct is established.

10. A healthcare economics framework for measuring corruption risk

Healthcare institutions often measure budgets, expenditure, procurement savings and service volumes. They should also assess the risks that threaten the value of those expenditures.

A useful framework can combine financial, operational and clinical indicators.

DimensionWhat should be measured?
Procurement integrityCompetition, price deviations, justified exceptions and compliance with tender rules
Financial controlAudit observations, unexplained payments and timely reconciliation
Delivery performanceOn-time delivery, specification compliance and verified acceptance
Asset utilisationEquipment uptime, utilisation and maintenance performance
Medicine availabilityStock-outs, inventory discrepancies and expiry-related losses
Patient impactTreatment delays, service interruptions and relevant clinical outcomes
AccountabilityCorrective actions completed and independently verified

These indicators should be interpreted in context. A high number of audit observations may reflect stronger detection rather than worse underlying performance, while a low number may reflect inadequate scrutiny.

The purpose of the framework is to identify risks, improve decision-making and establish whether corrective actions work—not to create a simplistic league table of hospitals or governments.

Conclusion: The real cost of healthcare corruption is the care that public money fails to deliver

Recent developments in Delhi have highlighted serious questions about medical procurement, public infrastructure, inventory control and institutional accountability.

The alleged procurement fraud requires a fair and thorough investigation. The reported medicine disappearance requires the facts to be established. Questions about hospital projects and service delivery deserve scrutiny through reliable records and independent assessment.

None of these cases should be prejudged. Equally, they should not be dismissed as merely political controversies when they concern resources intended for public healthcare.

The broader lesson is that healthcare governance must be designed around the protection of public value.

Every rupee allocated to a government hospital has an intended purpose: to provide medicines, diagnostic capacity, trained personnel, safe infrastructure and effective treatment. When expenditure fails to deliver those outcomes, whether through alleged corruption, weak controls or administrative failure, the public loses more than money.

It loses potential healthcare capacity.

India needs transparent procurement, competent administration, independent oversight, reliable inventory systems and accountability grounded in evidence. It also needs to measure public expenditure by what hospitals can actually deliver to patients.

The ultimate test of healthcare governance is not how much money is sanctioned, how many contracts are awarded or how many investigations are announced. It is whether public resources are converted into accessible, safe and effective healthcare—and whether every allegation of wrongdoing is examined fairly and responsibly.

That is how trust in public healthcare can be strengthened: not through slogans, but through systems that protect public money, uphold due process and put patients first.